相关实验视频

Updated: Mar 6, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

活动模式的变化与脑缩和多发性硬化症患者残疾进展的关联

Kathryn C Fitzgerald¹, Muraleetharan Sanjayan¹, Blake E Dewey¹

¹Division of Neuroimmunology and Neurological Infections, Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD; and.

|March 4, 2026

概括

多发性硬化症 (PwMS) 患者白天活动减少预示着残疾和大脑缩的恶化. 加速度计提供了一种敏感的,非侵入性的方法来追踪这些细微的,疾病进展的早期变化.

科学领域:

神经学神经学
生物医学工程生物医学工程
康复科学康复科学康复科学

背景情况:

多发性硬化症 (MS) 是一种慢性神经系统疾病,其特点是逐渐残疾.
日常活动的微妙变化可能表明MS (PwMS) 患者的早期疾病进展.
对身体活动的客观监测对于了解疾病轨迹至关重要.

研究的目的:

确定加速度计是否可以检测到PwMS中残疾的微妙,纵向变化.
评估加速计衍生活动测量与个体水平上大脑缩和残疾恶化之间的关系.

主要方法:

在3年内对238名PwMS (年龄≥40) 进行长度研究,每年使用脑MRI和每季度使用加速度计.
加速度计测量了总活动,静坐时间和昼夜节律参数.
通过扩展残疾状况尺度加 (EDSS+) 评估残疾恶化;通过全脑细分评估大脑缩.

主要成果:

总活动的年均下降率为2.0%.
在人体内减少白天活动 (8:00-14:00) 显著预测EDSS+证实残疾进展的风险更高.
晨间活动的下降与全脑,深灰质和thalamic体积损失的增加相关.

结论:

在PwMS中,白天活动模式的减少先于临床残疾恶化和大脑缩.
纵向加速度计显示,作为一种敏感的,非侵入性的生物标志物,可用于检测MS中亚临床疾病进展.
需要进一步的研究来确定加速度计测量的值和响应能力.

更多相关视频

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease

Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease

Published on: June 9, 2018

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...